Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer

Human Pathology

Volumn 44, Issue 8, 2013, Pages 1524-1533

  Bohn, B A ^a   Mina, S ^a   Krohn, A ^a   Simon, R ^a   Kluth, M ^a   Harasimowicz, S ^a   Quaas, A ^a   Bockhorn, M ^a   Izbicki, J R ^a   Sauter, G ^a   Marx, A ^a   Stahl, P R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Colorectal neoplasms; Fluorescence in situ hybridization; Gene deletion; PTEN phosphohydrolase

Indexed keywords

MISMATCH REPAIR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; COLON CANCER; COLORECTAL LIVER METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DISRUPTION; GENE REARRANGEMENT; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN FUNCTION; RECTUM CANCER; RECURRENT CANCER; TISSUE MICROARRAY; TISSUE SECTION;

COLORECTAL NEOPLASMS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; PTEN PHOSPHOHYDROLASE;

AGED; COLONIC NEOPLASMS; FEMALE; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PTEN PHOSPHOHYDROLASE; RECTAL NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880325080     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.12.006     Document Type: Article

References (40)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
3. D.M. Li, and H. Sun TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta Cancer Res 57 1997 2124 2129
4. J. Schlessinger, and M.A. Lemmon Nuclear signaling by receptor tyrosine kinases: the first robin of spring Cell 127 2006 45 48
5. S. Siena, A. Sartore-Bianchi, and F. Di Nicolantonio Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
6. F.V. Negri, C. Bozzetti, and C.A. Lagrasta PTEN status in advanced colorectal cancer treated with cetuximab Br J Cancer 102 2010 162 164
7. F. Perrone, A. Lampis, and M. Orsenigo PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 2009 84 90
8. E. Razis, E. Briasoulis, and E. Vrettou Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study BMC Cancer 8 2008 234
9. M.F. Berger, M.S. Lawrence, and F. Demichelis The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
10. P.C. Verhagen, P.W. van Duijn, and K.G. Hermans The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion J Pathol 208 2006 699 707
11. A. Krohn, T. Diedler, and L. Burkhardt Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer Am J Pathol 181 2012 401 412
12. J.G. Chang, Y.J. Chen, and L.I. Perng Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract Eur J Cancer 35 1999 647 651
13. J.M. Garcia, R. Rodriguez, and J. Silva Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer Ann Surg Oncol 10 2003 876 881
14. A. Goel, C.N. Arnold, and D. Niedzwiecki Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers Cancer Res 64 2004 3014 3021
15. M. Karoui, C. Tresallet, and C. Julie Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases Br J Cancer 90 2004 1230 1234
16. N.T. Nassif, G.P. Lobo, and X. Wu PTEN mutations are common in sporadic microsatellite stable colorectal cancer Oncogene 23 2004 617 628
17. X.P. Zhou, A. Loukola, and R. Salovaara PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers Am J Pathol 161 2002 439 447
18. X.H. Li, H.C. Zheng, and H. Takahashi PTEN expression and mutation in colorectal carcinomas Oncol Rep 22 2009 757 764
19. M. Berg, S.A. Danielsen, and T. Ahlquist DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset PLoS One 5 2010 e13978
20. G. Dicuonzo, S. Angeletti, and J. Garcia-Foncillas Colorectal carcinomas and PTEN/MMAC1 gene mutations Clin Cancer Res 7 2001 4049 4053
21. G. Guanti, N. Resta, and C. Simone Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis Hum Mol Genet 9 2000 283 287
22. L. Agell, S. Hernandez, and S. de Muga KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations Mod Pathol 21 2008 1470 1478
23. J. Abubaker, P. Bavi, and S. Al-Harbi Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population Oncogene 27 2008 3539 3545
24. W.C. Chen, M.S. Lin, and B.F. Zhang Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray World J Gastroenterol 13 2007 699 708
25. T. Colakoglu, S. Yildirim, and F. Kayaselcuk Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am J Surg 195 2008 719 725
26. M. Frattini, P. Saletti, and E. Romagnani PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 97 2007 1139 1145
27. C.P. Hsu, T.Y. Kao, and W.L. Chang Clinical significance of tumor suppressor PTEN in colorectal carcinoma Eur J Surg Oncol 37 2011 140 147
28. K.S. Jang, Y.S. Song, and S.H. Jang Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma Histopathology 56 2010 229 239
29. P. Laurent-Puig, A. Cayre, and G. Manceau Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 2009 5924 5930
30. F.H. Li, L. Shen, and Z.H. Li Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer World J Gastroenterol 16 2010 5881 5888
31. F. Loupakis, L. Pollina, and I. Stasi PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer J Clin Oncol 27 2009 2622 2629
32. J.H. Park, S.W. Han, and D.Y. Oh Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer Cancer Chemother Pharmacol 68 2011 1045 1055
33. H. Sawai, A. Yasuda, and N. Ochi Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival BMC Gastroenterol 8 2008 56
34. K. Taniyama, S. Goodison, and R. Ito PTEN expression is maintained in sporadic colorectal tumours J Pathol 194 2001 341 348
35. G. Sauter, J. Lee, and J.M. Bartlett Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 2009 1323 1333
36. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
37. T.L. Lotan, B. Gurel, and S. Sutcliffe PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Clin Cancer Res 17 2011 6563 6573
38. J.A. Bufill Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location Ann Intern Med 113 1990 779 788
39. A. Marx, P. Simon, and R. Simon AMACR expression in colorectal cancer is associated with left-sided tumor localization Virchows Arch 453 2008 243 248
40. M.F. Kalady, J.A. Sanchez, and E. Manilich Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas Dis Colon Rectum 52 2009 1039 1045